Suppr超能文献

2018 - 2022年呼吸道合胞病毒感染在西班牙充血性心力衰竭成人患者住院和死亡中的作用

The Role of Respiratory Syncytial Virus Infection in the Hospitalization and Mortality of Adults with Congestive Heart Failure in Spain, 2018-2022.

作者信息

Gómez-García Rosa María, Jiménez-García Rodrigo, López-de-Andrés Ana, Hernández-Barrera Valentín, Jimenez-Sierra Ana, Cuadrado-Corrales Natividad, Zamorano-León José Javier, Carabantes-Alarcón David, Bodas-Pinedo Andrés, De-Miguel-Díez Javier

机构信息

Respiratory Care Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense de Madrid, 28007 Madrid, Spain.

Department of Public Health & Maternal and Child Health, Faculty of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain.

出版信息

Viruses. 2025 Apr 1;17(4):516. doi: 10.3390/v17040516.

Abstract

(1) Background: Heart failure (HF) is a growing health concern, with decompensations being a major cause of hospital admissions. Respiratory syncytial virus (RSV) infection can trigger HF exacerbations, increasing morbidity and mortality. This study analyzed hospitalizations for HF with RSV infection in Spain from 2018 to 2022 using data from the Spanish Hospital Discharge Database. (2) Methods: We included patients aged ≥40 years with a diagnosis of HF, selecting a matched control group without RSV infection based on the HF diagnostic code position, year of admission, sex, and age. (3) Results: Of 424,413 HF hospitalizations, 0.47% (1988) involved RSV infection. Hospitalizations for HF with RSV increased over time, except for a decline in 2020-2021. ICU admissions and hospital length of stay decreased, but in-hospital mortality and costs remained unchanged. Patients with RSV had fewer comorbidities than those without RSV but experienced a higher mortality, more frequent non-invasive ventilation, longer hospital stays, and greater costs. Factors linked to higher mortality included advanced age, myocardial infarction, SARS-CoV-2 coinfection, and oxygen therapy dependence. RSV infection was independently associated with increased in-hospital mortality. (4) Conclusions: These findings highlight the need for early RSV detection in HF patients to implement preventive measures and reduce severe disease outcomes.

摘要

(1) 背景:心力衰竭(HF)是一个日益严重的健康问题,失代偿是住院的主要原因。呼吸道合胞病毒(RSV)感染可引发心力衰竭加重,增加发病率和死亡率。本研究利用西班牙医院出院数据库的数据,分析了2018年至2022年西班牙RSV感染导致心力衰竭的住院情况。(2) 方法:我们纳入了年龄≥40岁且诊断为心力衰竭的患者,并根据心力衰竭诊断代码位置、入院年份、性别和年龄选择了一个无RSV感染的匹配对照组。(3) 结果:在424413例心力衰竭住院病例中,0.47%(1988例)涉及RSV感染。RSV感染导致的心力衰竭住院病例随时间增加,但在2020 - 2021年有所下降。重症监护病房(ICU)入院率和住院时间缩短,但住院死亡率和费用保持不变。与无RSV感染的患者相比,RSV感染患者的合并症较少,但死亡率更高,无创通气更频繁,住院时间更长,费用更高。与较高死亡率相关的因素包括高龄、心肌梗死、SARS-CoV-2合并感染和氧疗依赖。RSV感染与住院死亡率增加独立相关。(4) 结论:这些发现凸显了在心力衰竭患者中早期检测RSV以实施预防措施并减少严重疾病后果的必要性。

相似文献

2
Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023.
JAMA Netw Open. 2024 Nov 4;7(11):e2444756. doi: 10.1001/jamanetworkopen.2024.44756.
4
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.
JAMA Netw Open. 2024 Dec 2;7(12):e2450832. doi: 10.1001/jamanetworkopen.2024.50832.
5
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD009417. doi: 10.1002/14651858.CD009417.pub3.
6
Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013757. doi: 10.1002/14651858.CD013757.pub2.

本文引用的文献

1
Hospitalization Following Outpatient Diagnosis of Respiratory Syncytial Virus in Adults.
JAMA Netw Open. 2024 Nov 4;7(11):e2446010. doi: 10.1001/jamanetworkopen.2024.46010.
2
Burden of Respiratory Syncytial Virus-Associated Hospitalizations in US Adults, October 2016 to September 2023.
JAMA Netw Open. 2024 Nov 4;7(11):e2444756. doi: 10.1001/jamanetworkopen.2024.44756.
3
Global epidemiology of heart failure.
Nat Rev Cardiol. 2024 Oct;21(10):717-734. doi: 10.1038/s41569-024-01046-6. Epub 2024 Jun 26.
4
Respiratory Syncytial Virus Infection in Older Adults: An Update.
Drugs Aging. 2024 Jun;41(6):487-505. doi: 10.1007/s40266-024-01118-9. Epub 2024 May 7.
5
Arexvy: A Comprehensive Review of the Respiratory Syncytial Virus Vaccine for Revolutionary Protection.
Viral Immunol. 2024 Jan-Feb;37(1):12-15. doi: 10.1089/vim.2023.0093. Epub 2024 Feb 5.
6
Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper.
Arch Bronconeumol. 2024 Mar;60(3):161-170. doi: 10.1016/j.arbres.2024.01.004. Epub 2024 Jan 17.
7
The Annual Economic Burden of Respiratory Syncytial Virus in Adults in the United States.
J Infect Dis. 2024 Aug 16;230(2):e342-e352. doi: 10.1093/infdis/jiad559.
9
Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation.
Cureus. 2023 Mar 18;15(3):e36342. doi: 10.7759/cureus.36342. eCollection 2023 Mar.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验